Video
Dr. Axel Grothey on Differences Between CORRECT and CONCUR Studies in mCRC
Author(s):
Axel Grothey, MD, department of Oncology, Mayo Clinic, Rochester, MN, discusses the differences between the CORRECT and CONCUR trials, which both looked at regorafenib for previously treated metastatic colorectal cancer (mCRC).
Axel Grothey, MD, department of Oncology, Mayo Clinic, Rochester, MN, discusses the differences between the CORRECT and CONCUR trials, which both looked at regorafenib for previously treated metastatic colorectal cancer (mCRC).
In the international phase III CORRECT trial, a survival benefit was observed with regorafenib over placebo in mCRC, gaining FDA approval for the drug.
The CORRECT trial included 760 patients from North America, Europe, Australia, and Asia. However only four Chinese patients were enrolled in the trial due to rapid accruement, said Grothey.
The CONCUR trial, which was also a phase III trial, was conducted to confirm the effectiveness of regorafenib in Asian mCRC patients and included 204 patients from Asian countries, including 172 Chinese patients. The patients in this trial were also not as heavily pre-treated in CONCUR as in CORRECT, resulting in an even more significant survival benefit.
